{"nctId":"NCT01068626","briefTitle":"Rosuvastatin in Visceral Adiposity","startDateStruct":{"date":"2006-05"},"conditions":["Abdominal Obesity"],"count":54,"armGroups":[{"label":"Rosuvastatin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Rosuvastatin"]},{"label":"Placebo for Rosuvastatin","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo for rosuvastatin"]}],"interventions":[{"name":"Rosuvastatin","otherNames":["CrestorÂ®"]},{"name":"Placebo for rosuvastatin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male patients between 40 and 65 years of age.\n* Abdominal obesity\n* Dyslipidemia\n* Written informed consent.\n\nExclusion Criteria:\n\n* Uncontrolled hypertension\n* Diabetes mellitus\n* Severe liver disease\n* Severely reduced renal function\n* Uncontrolled endocrine disorders\n* History of or ongoing malignant disease\n* Patients with known myopathic disease\n* Recent alcohol or drug abuse\n* Weight loss or weight gain during the three months prior to screening.\n* Ongoing treatment with statins\n* Ongoing treatment with calcineurin-inhibitors\n* Ongoing treatment with anti-inflammatory drugs\n* Received an investigational drug within 30 days prior to screening.\n* Strong clinical indication for statin treatment\n* In the Principal Investigator's opinion, the patient has other clinically significant cardiac, oncologic, neurologic or psychiatric disease that could be adversely affected by Study participation.\n* For any reason the patient is considered by the Principal Investigator to be an unsuitable candidate to participate in the Study.","healthyVolunteers":false,"sex":"MALE","minimumAge":"40 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Visceral Adipose Tissue Area Measured by Computed Tomography.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"27"},{"groupId":"OG001","value":"2.8","spread":"26"}]}]}]},{"type":"SECONDARY","title":"Change in Subcutaneous Adipose Tissue Area","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":"34"},{"groupId":"OG001","value":"1","spread":"15"}]}]}]},{"type":"SECONDARY","title":"Change in the Ratio Between Intra-abdominal and Subcutaneous Tissue Area Measured by CT.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.11"},{"groupId":"OG001","value":"0.01","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Change in Hepatic Fat Infiltration Measured by CT.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"5.2"},{"groupId":"OG001","value":"-2","spread":"5.0"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"2.6"},{"groupId":"OG001","value":"0.5","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Change in LDL","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"0.9"},{"groupId":"OG001","value":"-0.1","spread":"0.9"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":30},"commonTop":["Dyspepsia"]}}}